Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[DTIC: effect on fibrinolysis and thrombocyte function].

H Biltz, U Budde, U Fiedler

    Onkologie
    |October 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Generalized seizure during placement of an axillary plexus block].

    Der Anaesthesist·2021
    Same author

    Ex vivo human placental transfer study on recombinant Von Willebrand factor (rVWF).

    Placenta·2021
    Same author

    Acquired von Willebrand syndrome in congenital heart disease surgery: results from an observational case-series.

    Journal of thrombosis and haemostasis : JTH·2018
    Same author

    An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.

    Journal of thrombosis and haemostasis : JTH·2018
    Same author

    Lupus anticoagulants associated inhibitor against factor IX in a young patient with haemophilia B.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

    Journal of thrombosis and haemostasis : JTH·2016

    The cause of Budd-Chiari syndrome during dacarbacin (DTIC) cancer treatment remains unclear. Research indicates that DTIC treatment does not appear to cause this condition through blood clotting issues.

    Area of Science:

    • Hematology
    • Oncology
    • Pathophysiology

    Context:

    • Budd-Chiari syndrome is a rare condition affecting liver blood flow.
    • Dacarbacin (DTIC) is used in treating malignant melanoma.
    • The pathogenesis of Budd-Chiari syndrome during DTIC treatment is not well understood.

    Purpose:

    • To investigate the potential link between dacarbacin (DTIC) treatment and the development of Budd-Chiari syndrome.
    • To explore whether hemostaseological impairment plays a role in this adverse event.

    Summary:

    • This study investigated the pathogenesis of Budd-Chiari syndrome in patients treated with dacarbacin (DTIC).
    • No evidence was found to support the hypothesis that DTIC treatment causes Budd-Chiari syndrome via hemostaseological impairment.

    Related Experiment Videos

    Impact:

    • Findings suggest that blood clotting disorders are unlikely to be the cause of Budd-Chiari syndrome in patients receiving DTIC.
    • This research helps to clarify the potential side effects of dacarbacin, guiding clinical management and patient safety.